博安生物(06955)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06955 博安生物

午间休市 11-11 11:55:47

3.070

-0.015

-0.49%

最高3.085	最低3.025	成交量1.58万
今开3.085	昨收3.085	日振幅1.94%
总市值18.85亿	流通市值18.85亿	总股本6.14亿
成交额4.84万	换手率0.00%	流通股本6.14亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06955","market":"HK","secType":"STK","nameCN":"博安生物","latestPrice":3.07,"timestamp":1794369347958,"preClose":3.085,"halted":0,"volume":15800,"delay":0,"changeRate":-0.004862236628849311,"floatShares":614000000,"shares":614000000,"eps":0.012412,"marketStatus":"午间休市","change":-0.015,"latestTime":"11-11 11:55:47","open":3.085,"high":3.085,"low":3.025,"amount":48372,"amplitude":0.019449,"askPrice":3.07,"askSize":1400,"bidPrice":3.035,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-0.185577,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794373200000},"marketStatusCode":3,"adr":0,"listingDate":1672329600000,"exchange":"SEHK","adjPreClose":3.085,"openAndCloseTimeList":[[1794360600000,1794369600000],[1794373200000,1794384000000]],"volumeRatio":0.077756,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06955","defaultTab":"news","newsList":[{"id":"2681834543","title":"港股异动 | 博安生物(06955)午后涨超4% BA2201在中国获批开展临床 拟用于治疗炎症性肠病","url":"https://stock-news.laohu8.com/highlight/detail?id=2681834543","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681834543?lang=zh_cn&edition=full","pubTime":"2026-11-06 14:24","pubTimestamp":1793946264,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，博安生物午后涨超4%，截至发稿，涨4.33%，报3.01港元，成交额116.78万港元。消息面上，博安生物午间发布公告，公司自主开发的1类创新药BA2201已获得中国国家药品监督管理局药品审评中心批准开展临床试验。公司指，随着BA2201进入临床阶段，公司将加速推进后续研究，加快验证这一兼顾双靶点干预与长期给药便利性的治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","06955","BK4588","BK1161","VXUS","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681836367","title":"博安生物(06955)：BA2201(TL1A/IL-23)在中国获批开展临床，拟用于治疗炎症性肠病","url":"https://stock-news.laohu8.com/highlight/detail?id=2681836367","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681836367?lang=zh_cn&edition=full","pubTime":"2026-11-06 12:28","pubTimestamp":1793939305,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 发布公告，公司自主开发的1类创新药BA2201已获得中国国家药品监督管理局药品审评中心批准开展临床试验。该在研药物为靶向TL1A及IL-23的长效双特异性抗体，拟用于治疗炎症性肠病等自身免疫性疾病。针对上述临床需求，BA2201同时靶向IL-23和TL1A两条IBD核心致病通路。BA2201治疗潜力在动物模型中获得初步验证。在小鼠结肠炎模型中，BA2201显示出优异的抗炎效果，相比TL1A单抗或IL-23单抗疗效更优。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519503.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["307180.KR","06955","BK9021","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165151818","title":"博安生物（06955）双特异性抗体BA2201获中国NMPA批准启动IBD临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1165151818","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165151818?lang=zh_cn&edition=full","pubTime":"2026-11-06 12:12","pubTimestamp":1793938372,"startTime":"0","endTime":"0","summary":"2026年11月6日，博安生物（06955）公告称，其自主开发的1类创新药BA2201已获国家药品监督管理局药品审评中心（CDE）批准在中国开展临床试验，靶向适应症为炎症性肠病（IBD）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170784172","title":"博安生物10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1170784172","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170784172?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:06","pubTimestamp":1793869574,"startTime":"0","endTime":"0","summary":"山东博安生物技术股份有限公司（简称“博安生物”，股票代码：06955）于2026年11月5日发布2026年10月股份变动月报表，报告期截至2026年10月31日。根据公告显示，公司本月无新增股份发行或购回及注销行为，整体股本保持不变。\n报告期末，公司注册股本为622,333,694股；其中已发行股份（不含库藏股）613,633,694股，库藏股份8,700,000股，总股本与上月底一致。公司确认已符合适用的公众持股量要求，并表示本月度的各项证券发行及库藏股份相关事宜均遵守香港联交所《上市规则》及相关法律法规。该月报表由公司董事姜华签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121510935","title":"博安生物（06955）将地舒单抗生物类似药授权日本伙伴独家商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=1121510935","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121510935?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:36","pubTimestamp":1793353003,"startTime":"0","endTime":"0","summary":"2026年10月30日，山东博安生物技术股份有限公司公告称，已就地舒单抗注射液60 mg在日本市场的独家商业化权益，与合作伙伴签署授权合作协议。根据协议，合作伙伴将负责BA6101在日本的推广、销售及注册申报，并承担该产品在当地的开发与准入工作；博安生物将获得首付款、里程碑付款及销售提成。日本政府目标是在2029财年末实现至少60%已有生物类似药品种的替代率达到80%。博安生物表示，将与合作伙伴整合资源，共同提升地舒单抗在日本的可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679729968","title":"博安生物(06955.HK)：地舒单抗注射液60mg在日本达成授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2679729968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679729968?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:32","pubTimestamp":1793352740,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177695735","title":"博安生物06955：BA1203中国I期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1177695735","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177695735?lang=zh_cn&edition=full","pubTime":"2026-10-22 18:06","pubTimestamp":1792663562,"startTime":"0","endTime":"0","summary":"2026年10月22日，博安生物公告称，公司在研PD-1/IL-2抗体细胞因子前药BA1203的中国I期临床试验已完成首例受试者入组。该试验为多中心、开放性研究，主要评估BA1203在晚期实体瘤患者中的安全性、耐受性、药代动力学和初步疗效。公司表示，据其了解，BA1203是全球唯一具备IL-2α受体高活性、遮蔽型且PD-1阻断功能的PD-1/IL-2分子。博安生物计划加快推进BA1203的临床开发，进一步探索其在多种实体瘤中的单药及联合治疗潜力。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677895955","title":"博安生物(06955.HK)：BA1203(遮蔽型PD-1/IL-2)中国I期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2677895955","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677895955?lang=zh_cn&edition=full","pubTime":"2026-10-22 18:03","pubTimestamp":1792663401,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674429888","title":"博安生物与南京绿叶订立推广合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2674429888","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674429888?lang=zh_cn&edition=full","pubTime":"2026-10-12 08:35","pubTimestamp":1791765300,"startTime":"0","endTime":"0","summary":"模拟交易客户端博安生物发布公告，于2026年10月9日，本公司与南京绿叶订立推广合作协议，南京绿叶将为本公司的指定产品提供推广及营销服务，期限自2026年10月9日起至2027年9月30日止。本公司认为，通过订立推广合作协议，本集团将能够利用南京绿叶的营销专业知识及资源，提升产品的市场渗透及品牌知名度。南京绿叶将提供的推广及营销服务将支持本集团生物类似药及生物制品的商业化策略，并预期有助于本集团来自产品的收入增长。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-10-12/doc-iniuxmtr7176778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674857298","title":"博安生物(06955)与南京绿叶订立推广合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2674857298","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674857298?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:04","pubTimestamp":1791554652,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 发布公告，于2026年10月9日，本公司与南京绿叶订立推广合作协议，南京绿叶将为本公司的指定产品提供推广及营销服务，期限自2026年10月9日起至2027年9月30日止。本公司认为，通过订立推广合作协议，本集团将能够利用南京绿叶的营销专业知识及资源，提升产品的市场渗透及品牌知名度。南京绿叶将提供的推广及营销服务将支持本集团生物类似药及生物制品的商业化策略，并预期有助于本集团来自产品的收入增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132512277","title":"博安生物9月股份变动月报表：回购670万股H股并增加库存股至870万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1132512277","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132512277?lang=zh_cn&edition=full","pubTime":"2026-10-07 16:37","pubTimestamp":1791362230,"startTime":"0","endTime":"0","summary":"博安生物于2026年10月7日发布了截至2026年9月30日的股份变动月报表。报告显示，截至9月底，公司注册股本总额为622,333,694股，与上月底保持一致。根据月报，博安生物的已发行股份由上月底的620,333,694股减少至613,633,694股，主要原因在于当月回购了合计6,700,000股H股并将其改为库藏股；该部分库藏股份则由上月底的2,000,000股增加至8,700,000股，回购价格在每股港币2.55至3.44之间，回购日期主要集中在2026年9月4日至9月17日。该月报由公司董事姜华代表签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671293354","title":"创新药概念股逆市走强 康方生物（09926）涨16.85%、康诺亚-B（02162）涨10.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671293354","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671293354?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:20","pubTimestamp":1790659249,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股逆市走强，康方生物 涨16.85%，康诺亚-B涨10.32%，乐普生物涨7.88%，荣昌生物涨5.41%，科伦博泰生物涨5.32%，博安生物涨4.74%，恒瑞医药涨4.02%，再鼎医药涨4.02%。根据Insight数据，除已经在美国获批上市的药物外，已达成出海合作的国产创新药中有27款处于临床后期。其中，依沃西单抗、匹米替尼已在美国申请上市，芦康沙妥珠单抗、伦康依隆妥单抗、SSGJ-707等重点品种处于临床III期。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992749","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","LU1720050803.USD","LU1794554557.SGD","IE00BPRC5H50.USD","09688","LU0561508036.HKD","LU0348825331.USD","LU0348783233.USD","LU2476274720.SGD","LU0348827113.USD","09926","06990","09995","BK1191","LU0634319403.HKD","BK1588","02157","LU2778985437.USD","LU2476274308.USD","LU1961090484.USD","BK1161","LU0196878994.USD","MEDX","KURE","159992","LU1023057109.AUD","06955","LU0359201612.USD","LNGR","LU1969619763.USD","06978","LU0359201885.HKD","LU0417516902.SGD","LU2328871848.SGD","LU2543165471.USD","LU0348767384.USD","LU0348784397.USD","LU0348766576.USD","BK1583","IBBQ","IE00B5MMRT66.SGD","BK1574","LU0359202008.SGD","LU0417516571.SGD","LU0348735423.USD","01276","LU0417516738.SGD","BK1587","02162","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669450139","title":"港股异动 | 博安生物(06955)尾盘涨超8% BA1203获国家药监局批准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2669450139","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669450139?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:43","pubTimestamp":1790235833,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，博安生物尾盘涨超8%。消息面上，博安生物近日宣布，公司在研PD-1/IL-2抗体细胞因子前药BA1203的新药临床试验申请已获得中国国家药品监督管理局药品审评中心批准，拟开发用于多种实体瘤的治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500408.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","BK4588","BMED","KCAI","BK1161","PSYK","06955","IBBQ","BK4585","IBBJ","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127750336","title":"博安生物9月17日回购30万股，耗资约76.51万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127750336","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127750336?lang=zh_cn&edition=full","pubTime":"2026-09-17 18:41","pubTimestamp":1789641681,"startTime":"0","endTime":"0","summary":"2026年9月17日，山东博安生物技术股份有限公司发布翌日披露报表，宣布当日于香港联交所场内回购H股30万股，约占回购前已发行股本的0.0489%。回购价格介乎每股2.47港元至2.585港元，总耗资约76.51万港元。根据股东大会于2026年6月22日通过的购回授权，博安生物可购回合计62,233,369股股份，迄今已累计回购8,700,000股，占当日获授权时已发行股份总数的1.398%。博安生物确认已就本次回购事项履行相关董事会决议，并遵守香港联交所证券上市规则及其他法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博安生物9月17日回购30万股，耗资约76.51万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668966678","title":"博安生物(06955.HK)9月17日斥资约76.51万港元回购30万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668966678","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668966678?lang=zh_cn&edition=full","pubTime":"2026-09-17 18:32","pubTimestamp":1789641156,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667603886","title":"港股异动 | 博安生物(06955.HK)涨近4% BA1203(遮蔽型PD-1/IL-2)临床试验获批 拟开发用于多种实体瘤治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667603886","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667603886?lang=zh_cn&edition=full","pubTime":"2026-09-16 15:11","pubTimestamp":1789542688,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667683266","title":"博安生物(06955.HK)：BA1203(遮蔽型PD-1/IL-2)在中国获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2667683266","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667683266?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:06","pubTimestamp":1789383973,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184734817","title":"博安生物（06955）获批开展BA1203在华临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1184734817","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184734817?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:06","pubTimestamp":1789383960,"startTime":"0","endTime":"0","summary":"2026年9月14日，博安生物公告称，公司自主研发的PD-1/IL-2抗体细胞因子前药BA1203的新药临床试验申请已获国家药监局药品审评中心批准，用于多种实体瘤治疗。博安生物计划开展一项多中心、开放性I期临床研究，评估BA1203在晚期实体瘤患者中的安全性、耐受性、药代动力学及初步疗效，并探索单药及联合治疗方案。公司表示，将通过进一步临床验证，充分评估BA1203在PD-1靶点结合、免疫通路阻断及肿瘤微环境免疫激活等方面的治疗潜力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139435180","title":"博安生物9月11日回购50万股，涉资约141.41万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1139435180","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139435180?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:06","pubTimestamp":1789121192,"startTime":"0","endTime":"0","summary":"2026年9月11日，博安生物发布翌日披露报表。公告显示，公司于2026年9月11日于香港联合交易所场内回购H股50万股，占回购前公司已发行股份总数约0.0814%。本次回购价格介乎每股2.775港元至2.91港元，平均回购价约2.8281港元，涉资约141.41万港元。此前，公司于2026年6月22日通过回购授权，可回购总数为62,233,369股。公告同时披露，公司已遵守香港联合交易所有限公司的上市规则及相关法律法规，相关董事会已对本次回购予以正式授权。公告由公司董事姜华签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博安生物9月11日回购50万股，涉资约141.41万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666523215","title":"博安生物(06955)9月11日斥资141.41万港元回购50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666523215","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666523215?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:01","pubTimestamp":1789120895,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物(06955)发布公告，于2026年9月11日，该公司斥资141.41万港元回购50万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.boan-bio.com","stockEarnings":[{"period":"1week","weight":0.0283},{"period":"1month","weight":-0.0048},{"period":"3month","weight":-0.333},{"period":"6month","weight":-0.4934},{"period":"1year","weight":-0.7008},{"period":"ytd","weight":-0.6388}],"compareEarnings":[{"period":"1week","weight":0.0438},{"period":"1month","weight":0.0143},{"period":"3month","weight":-0.0347},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0785},{"period":"ytd","weight":-0.0419}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"山东博安生物技术股份有限公司是一家主要从事生物制药的中国公司。该公司主要从事治疗用抗体的开发、生产和商业化，专注于肿瘤学、代谢学、自身免疫学和眼科等治疗领域。该公司主要拥有三个技术平台：全人抗体转基因小鼠及噬菌体展示技术平台、双特异T-cell Engager技术平台、抗体药物偶联（ADC）技术平台。该公司主要在中国国内市场和海外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.161165},{"month":2,"riseRate":0.5,"avgChangeRate":-0.012143},{"month":3,"riseRate":0.25,"avgChangeRate":-0.003652},{"month":4,"riseRate":0.75,"avgChangeRate":0.065191},{"month":5,"riseRate":0.25,"avgChangeRate":-0.057252},{"month":6,"riseRate":0.25,"avgChangeRate":-0.04333},{"month":7,"riseRate":0.75,"avgChangeRate":0.130145},{"month":8,"riseRate":0,"avgChangeRate":-0.130814},{"month":9,"riseRate":0.5,"avgChangeRate":-0.020741},{"month":10,"riseRate":0.25,"avgChangeRate":-0.059447},{"month":11,"riseRate":0.25,"avgChangeRate":-0.023054},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.011932}],"exchange":"SEHK","name":"博安生物","nameEN":"BOAN BIOTECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博安生物(06955)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博安生物(06955)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博安生物,06955,博安生物股票,博安生物股票老虎,博安生物股票老虎国际,博安生物行情,博安生物股票行情,博安生物股价,博安生物股市,博安生物股票价格,博安生物股票交易,博安生物股票购买,博安生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博安生物(06955)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博安生物(06955)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}